About Nuclear pore glycoprotein p62
Nuclear pore glycoprotein p62 (NUP62) is a protein
from Homo sapiens identified by UniProt accession
P37198, 522 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | Nuclear pore glycoprotein p62 |
| UniProt accession | P37198 |
| Gene | NUP62 |
| Organism | Homo sapiens |
| Length | 522 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (74)
Diseases linked to this target (Open Targets).
- infantile bilateral striatal necrosis · score 0.55
- HIV infection · score 0.54
- influenza · score 0.54
- viral disease · score 0.53
- familial infantile bilateral striatal necrosis · score 0.53
- Histiocytosis · score 0.37
- COVID-19 · score 0.37
- clear cell renal carcinoma · score 0.28
- age at menopause · score 0.25
- breast adenocarcinoma · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P37198-F1 | alphafold | PREDICTED | 57.92 | — |
Amino-acid sequence (522 residues)
MSGFNFGGTG APTGGFTFGT AKTATTTPAT GFSFSTSGTG GFNFGAPFQP ATSTPSTGLF SLATQTPATQ TTGFTFGTAT LASGGTGFSL GIGASKLNLS NTAATPAMAN PSGFGLGSSN LTNAISSTVT SSQGTAPTGF VFGPSTTSVA PATTSGGFSF TGGSTAQPSG FNIGSAGNSA QPTAPATLPF TPATPAATTA GATQPAAPTP TATITSTGPS LFASIATAPT SSATTGLSLC TPVTTAGAPT AGTQGFSLKA PGAASGTSTT TSTAATATAT TTSSSSTTGF ALNLKPLAPA GIPSNTAAAV TAPPGPGAAA GAAASSAMTY AQLESLINKW SLELEDQERH FLQQATQVNA WDRTLIENGE KITSLHREVE KVKLDQKRLD QELDFILSQQ KELEDLLSPL EELVKEQSGT IYLQHADEER EKTYKLAENI DAQLKRMAQD LKDIIEHLNT SGAPADTSDP LQQICKILNA HMDSLQWIDQ NSALLQRKVE EVTKVCEGRR KEQERSFRIT FD
Explore Nuclear pore glycoprotein p62 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets